Galectin Therapeutics (GALT) Current Deferred Revenue (2010 - 2012)

Galectin Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $200000.0 for Q2 2012.

• On a quarterly basis, Current Deferred Revenue changed 0.0% year-over-year to $200000.0 in Q2 2012; TTM through Jun 2012 was $200000.0, a 0.0% change from a year earlier, with the FY2011 full-year figure at $200000.0, changed 0.0% from the prior year.
• Current Deferred Revenue steadied at $200000.0 in Q2 2012 per GALT's latest filing, from $200000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $200000.0 in Q4 2010 and bottomed at $200000.0 in Q4 2010.
• The 3-year median for Current Deferred Revenue is $200000.0 (2010), against an average of $200000.0.
• Biggest YoY gain for Current Deferred Revenue was 0.0% in 2011; the steepest drop was 0.0% in 2011.
• Year by year, Current Deferred Revenue stood at $200000.0 in 2010, then changed by 0.0% to $200000.0 in 2011, then changed by 0.0% to $200000.0 in 2012.
• Per Business Quant, the three latest GALT Current Deferred Revenue figures stand at $200000.0 (Q2 2012), $200000.0 (Q1 2012), and $200000.0 (Q4 2011).